Free Trial

Stoke Therapeutics (NASDAQ:STOK) Shares Up 18.1% - Time to Buy?

Stoke Therapeutics logo with Medical background

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price traded up 18.1% during trading on Tuesday . The company traded as high as $14.60 and last traded at $14.54. 476,404 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 679,777 shares. The stock had previously closed at $12.31.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on STOK. HC Wainwright lowered their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Jefferies Financial Group initiated coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $25.80.

Get Our Latest Stock Report on Stoke Therapeutics

Stoke Therapeutics Price Performance

The company's 50-day simple moving average is $11.30 and its two-hundred day simple moving average is $9.69. The firm has a market capitalization of $715.26 million, a P/E ratio of 17.10 and a beta of 1.14.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the transaction, the insider owned 25,782 shares of the company's stock, valued at approximately $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its holdings in Stoke Therapeutics by 29.2% during the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after acquiring an additional 4,512 shares during the period. GAMMA Investing LLC grew its holdings in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after buying an additional 52,813 shares during the period. Renaissance Technologies LLC bought a new stake in Stoke Therapeutics during the 4th quarter valued at about $1,423,000. Finally, ProShare Advisors LLC purchased a new stake in Stoke Therapeutics in the 4th quarter valued at about $139,000.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Featured Stories

Should You Invest $1,000 in Stoke Therapeutics Right Now?

Before you consider Stoke Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.

While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines